Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: INHALON BIOPHARMA, INC.
Awarding agency: Department of Defense / Defense Health Agency
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2025-09-22 to 2027-12-31
Current total value of award: $3175643
Description: A PHASE 1 PLACEBO-CONTROLLED DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF IN-007, A NEBULIZED, PAN-SARS ACE2-DECOY THERAPEUTIC FOR PANDEMIC PREPAREDNESS